Biogen Halts BIIB122 Idiopathic Parkinson’s Trial After Endpoint Miss, Shares Dip 1%
Biogen and Denali’s mid-stage LUMA trial of BIIB122 failed to meet primary and secondary endpoints in early-stage idiopathic Parkinson’s, leading to a 1% share decline after hours. They will halt broader development but pursue a genetic-mutation-targeted BEACON study with results due H1 2027.
1. LUMA Trial Misses Endpoints
Biogen and Denali’s mid-stage LUMA study of BIIB122 did not meet its primary or secondary goals on standard Parkinson’s rating scales, failing to slow motor and daily-living symptom progression. Biogen’s shares fell about 1% in after-hours trading following the announcement.
2. Safety Profile and Target Engagement
Despite the efficacy miss, BIIB122 demonstrated a strong safety profile with acceptable tolerability and confirmed target engagement of the LRRK2 protein in trial participants. No new safety signals were identified during the study.
3. Strategic Shift to Genetic Subgroup
Biogen and Denali will discontinue BIIB122 development for idiopathic Parkinson’s but will press ahead with Denali’s early-to-middle BEACON study targeting patients with LRRK2 gene mutations, with top-line results expected in the first half of 2027.